| Literature DB >> 28209653 |
Yanina Balabanova1,2,3, Lena Fiebig3, Olga Ignatyeva4, Vija Riekstina5, Manfred Danilovits6, Kaadri Jaama6, Edita Davidaviciene7, Birute Radiulyte7, Christina Marcela Popa8, Vladyslav Nikolayevskyy1,2,9, Francis Drobniewski1,2.
Abstract
WHO recently recommended the use of a shorter multidrug-resistant TB (MDR-TB) regimen under programmatic conditions. We assessed eligibility for this regimen in a cohort of 737 adult patients with MDR-TB from Latvia, Lithuania, Estonia and Bucharest city recruited in 2007 and 2009. Only 4.2% of the patients were eligible for this regimen. Ethambutol (64%), pyrazinamide resistance (58%) and previous exposure to second-line TB drugs were major reasons for non-eligibility. High-level resistance to isoniazid is expected due to widespread prevalence of katG mutations. In Eastern Europe, the use of the shorter regimen might be an exception rather than a rule. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.Entities:
Keywords: Tuberculosis
Mesh：
Substances：
Year: 2017 PMID： 28209653 DOI： 10.1136/thoraxjnl-2016-209841
Source DB: PubMed Journal: Thorax ISSN： 0040-6376 Impact factor: 9.139